Takeda's LIVTENCITY Gains Approval in Japan for Post-Transplant CMV Treatment

6/24/24 3:10:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TAK alert in real time by email

Takeda ((TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1

Get the next $TAK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TAK

Date	Price Target	Rating	Analyst
3/16/2023	$20.00	Neutral → Buy	BofA Securities
7/19/2022	$21.00 → $24.00	Market Perform → Outperform	Cowen
10/7/2021		Overweight → Equal-Weight	Morgan Stanley

More analyst ratings

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by Continued Advancement of Growth & Launch Products (+18.7% at CER) Core Operating Profit Increase of +12.9% at CER; Core Operating Profit Margin of 30.2% Double-Digit Revenue Growth of ENTYVIO® at CER Driven by Launch of ENTYVIO® Pen in the U.S. Geographical Expansion with Approvals of ADZYNMA® in EU and FRUZAQLA® in Japan Late-Stage Pipeline Advances with the Start of Phase 3 Trial of TAK-861 in Narcolepsy Type 1 Company will Hold R&D Day for Investors and Media on December 12 (Eastern) / 13 (Japan) Takeda ((4502, NYSE:TAK) today announced earnings results for the first half
10/31/24 2:05:00 AM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Ligand Reports Second Quarter 2024 Financial Results
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
8/6/24 4:01:00 PM ET
$AGEN
$AMGN
$CASI
$LGND
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$TAK
Leadership Updates

Live Leadership Updates

Vatroslav Mateljic Appointed General Manager of Takeda Canada
Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry. Mos
9/16/24 8:39:00 AM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave
3/26/24 7:07:00 PM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre
12/5/23 8:00:00 AM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care

$TAK
Press Releases

Fastest customizable press release news feed in the world

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto Universit
11/20/24 11:30:00 AM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
Approximately 300,000 Canadians are living with IBD, with the number projected to grow to 470,000 by 2035.1 TORONTO, Nov. 4, 2024 /CNW/ - Takeda Canada Inc. ("Takeda") announces new data highlighting the impact Inflammatory Bowel Disease (IBD) has on Canadians. The data reveals insights into how the disease affects daily life, the challenges to timely access to care and treatment, and the unmet need to prioritize mental health support for those living with IBD. The Takeda 300,000 Reasons Why Survey ["the survey"], conducted by Leger, a leading North American market research fi
11/4/24 8:01:00 AM ET
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care

$TAK
Market Insights

Live Market Insights

Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
7/24/24 3:18:18 PM ET
$ALMS
$BMY
$JNJ
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India
7/18/24 8:14:02 AM ET
$RDY
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor of α4β7 that is currently in Phase 2b trial for ulcerative colitis (UC), with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease (CD). Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst. Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd’s (NYSE:TAK) Entyvio, a mAb tar
7/9/24 2:59:19 PM ET
$LLY
$MORF
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care

Takeda's LIVTENCITY Gains Approval in Japan for Post-Transplant CMV Treatment

Chat with this insight

Recent Analyst Ratings for $TAK

$TAK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

$TAK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Takeda Pharma upgraded by BofA Securities with a new price target

Takeda Pharma upgraded by Cowen with a new price target

Takeda Pharmaceutical downgraded by Morgan Stanley

$TAK Financials

Live finance-specific insights

$TAK SEC Filings

$TAK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Ligand Reports Second Quarter 2024 Financial Results

SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

$TAK Leadership Updates

Live Leadership Updates

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

$TAK Press Releases

Fastest customizable press release news feed in the world

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

$TAK Market Insights

Live Market Insights

Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India

Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst

Recent Analyst Ratings for
$TAK

$TAK
Insider Trading

$TAK
Analyst Ratings

$TAK
Financials

$TAK
SEC Filings

$TAK
Large Ownership Changes

$TAK
Leadership Updates

$TAK
Press Releases

$TAK
Market Insights